Wegovy (semaglutide 2.4 mg) approved in the US for the treatment of MASH – Novo Nordisk
Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.




